DOCSLIB.ORG

Isopropyl Palmitate/White Soft Paraffin 2031

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Isopropyl Palmitate/White Soft Paraffin 2031 Isopropyl Palmitate/White Soft Paraffin 2031 Light Liquid Paraffin Preparations Yellow Soft Paraffin Dünnflüssiges Paraffin; Hígan folyó paraffin; Huile de Vaseline Flu- BP 2008: Cetomacrogol Emulsifying Ointment; Cetrimide Emulsifying Keltavaseliini; Minkštasis geltonas parafinas; Paraff. Moll. Flav.; Par- Ointment; Emulsifying Ointment; Light Liquid Paraffin Eye Drops; Liquid ide; Light Liquid Petrolatum; Light Mineral Oil; Light White Min- Paraffin and Magnesium Hydroxide Oral Emulsion; Liquid Paraffin Oral affinum Molle Flavum; Petrolatum; Petroleum Jelly; Sárga vazelin; eral Oil; Paraff. Liq. Lev.; Paraffin, lättflytande; Paraffine liquide Emulsion; Simple Eye Ointment; Wool Alcohols Ointment; Vaselin, gult; Vaselina Amarela; Vaselina amarilla; Vaselina filante légère; Paraffinum Liquidum Leve; Paraffinum Liquidum Tenue; USP 31: Bland Lubricating Ophthalmic Ointment; Mineral Oil Emulsion; amarilla; Vaseline jaune; Vaselinum flavum; Vazelína žlutá; Wazeli- Mineral Oil, Rectal; Topical Light Mineral Oil. Paraffinum perliquidum; Parafiini, kevyt nestemäinen; Parafin na z˙ółta; Yellow Petrolatum; Yellow Petroleum Jelly. tekutý lehký; Skystasis lengvas parafinas; Spray Paraffin; Vaselina Proprietary Preparations (details are given in Part 3) Arg.: Babix; Lansoyl; Lax Ewe Jalea; Laxante Arceli; Laxuave Enteral; Laxuave Жёлтый Вазелин líquida. Jalea; Lexavite†; Lubritina Franklin; Modaton NI; Oilatum; Austral.: Agarol; CAS — 8009-03-8. ATC — A06AA01. Hamilton Skin Therapy; Oilatum Bar; Oilatum Emollient; Oilatum Shower ATC Vet — QA06AA01. Gel; Belg.: Lansoyl; Braz.: Nujol; Canad.: Fleet Enema Mineral Oil; Lan- Pharmacopoeias. In Chin., Eur. (see p.vii), Int., Jpn, and US. soyl; Nujol; Chile: Laxonarol; Cz.: Oilatum Emollient; Oilatum Gel; Fr.: Lan- Many pharmacopoeias use the title Vaselinum Flavum; in some In Eur. (see p.vii) and Jpn. Also in USNF. soyl; Laxamalt†; Lubentyl; Oilatum Emollient; Oilatum Soap†; Restrical; Pharmacopoeias. countries the name ‘Vaseline’ is a trade-mark. US also includes Topical Light Mineral Oil . Ger.: Agarol N†; Obstinol M; Gr.: Agarol Plain; Nujol; Paragel; Hong Ph. Eur. 6.2 (Paraffin, Yellow Soft). A purified mixture of semi- . A purified mixture of liquid Kong: Agarol; Hamilton Body Wash; Keri; Oilatum Bar; Oilatum Emollient; Ph. Eur. 6.2 (Paraffin, Light Liquid) Oilatum Gel; Vigarol; Indon.: Oilatum Bar; Oilatum Gel; Irl.: Alcoderm†; solid hydrocarbons obtained from petroleum. A yellow, translu- saturated hydrocarbons obtained from petroleum. It is a transpar- Oilatum Gel; Oilatum Junior; Oilatum Soap; Ital.: Agarol CM†; Duratirs†; cent, unctuous mass, slightly fluorescent in daylight when melt- ent, colourless, oily liquid, free from fluorescence in daylight. Malaysia: Balneum; Egozite Protective Baby Lotion; Laxaron†; Oilatum; ed. It has a drop point of 40° to 60°. Practically insoluble in wa- Relative density 0.810 to 0.875. Viscosity 25 to 80 mPa s. Prac- NZ: Fleet Mineral Enema†; Oilatum; Philipp.: Oilatum; Pol.: Oilatum; S.Afr.: Oilatum Bar; Oilatum Emollient; Singapore: Balneum; Laxarol; Nu- ter, in alcohol, and in glycerol; slightly soluble in tically insoluble in water; slightly soluble in alcohol; miscible traderm†; Oilatum Bar; Oilatum Emollient; Oilatum Gel; Spain: Emuliquen dichloromethane. Protect from light. with hydrocarbons. Protect from light. Simple; Hodernal; Switz.: Lansoyl; Laxamalt; Paragol N; Thai.: Agarol; Oil- USP 31 (Petrolatum). A purified mixture of semi-solid hydro- . A purified mixture of liquid hy- atum Bar; Oilatum Emollient; Oilatum Gel; Turk.: Duratears; Sokol; UK: USNF 26 (Light Mineral Oil) carbons obtained from petroleum. It may contain a suitable sta- drocarbons obtained from petroleum. It may contain a suitable Cetraben Emollient; Dermamist; Keri; Oilatum Bath Formula; Oilatum Fra- grance Free; Oilatum Gel; Oilatum Junior; Oilatum Soap; Zerobase; USA: biliser. It is an unctuous yellowish to light amber mass, having stabiliser. It has similar characteristics to Mineral Oil but a lower Kondremul; Liqui-Doss. not more than a slight fluorescence even after being melted. It is kinematic viscosity. Store in airtight containers. Protect from Multi-ingredient: Arg.: Agarol; Alcon Lagrimas; Aqualane; Cold Cream transparent in thin layers. It is free or practically free from odour. light. Naturel†; Mil-Par; Usar Fibras†; Austral.: Alpha Keri; DermaVeen Shower & Bath; Dermeze; Duratears; E45; Egozite Baby Cream; Granugen; Hamil- M.p. 38° to 60°. Insoluble in water; practically insoluble in cold Adverse Effects and Precautions ton Body Lotion†; Hamilton Cleansing Lotion†; Hamilton Dry Skin; Lacri- or hot alcohol and in cold dehydrated alcohol; freely soluble in Excessive oral or rectal dosage with liquid paraffin may result in Lube; Oilatum Plus; Parachoc; Pinetarsol; Rikoderm†; Soov Prickly Heat; benzene, in carbon disulfide, in chloroform, and in turpentine oil; anal seepage and irritation, excessive purgation, and watery diar- Austria: Balneum F; Neda Fruchtewurfel; Belg.: Duratears; Lacrytube; soluble in ether, in petroleum spirit, and in most fixed and vola- Tulle Vaseline†; Braz.: Agarol; Balmex; Fenogar†; Parapsyl; Canad.: Agarol rhoea. Liquid paraffin is absorbed to a slight extent and may give Plain; Akwa Tears; Alpha Keri†; Duolube; Duratears†; Episec; Huile de Bain tile oils. rise to foreign-body granulomatous reactions. Similar reactions Therapeutique; Hypotears; Lubriderm Advanced Moisture†; Lubriderm†; have followed the injection of liquid paraffin and may be consid- Magnolax; Oilatum; Optilube; Penederm†; Puralube†; Refresh Lacri-Lube; Adverse Effects erably delayed in onset. Injection may also cause vasospasm and Tears Naturale PM; Therapeutic Bath Oil†; Therapeutic Skin Lotion†; Adverse effects of soft paraffin are rare when used in topical prompt surgical removal may be required to prevent severe dam- Chile: Acnaid; Acnoxyl Jabon†; Agarol; Cold Cream Avene; Durasolets; preparations, but sensitivity reactions and acne have been report- Duratears; Lacri-Lube; Cz.: Balmandol; Balneum Hermal F; Oilatum Plus; ed after topical use. Granulomatous reactions after absorption or age. Lipoid pneumonia has been reported after aspiration of liq- Denm.: Ojensalve Neutral; Fin.: Lacri-Lube; Fr.: Cerat Inalterable; Cold uid paraffin. Because of the risk of aspiration, oral liquid paraffin Cream Naturel; Dexeryl; Lubentyl a la Magnesie; Melaxose; Oilatum Body injection and lipoid pneumonia after aspiration have occurred. should not be given to patients who have difficulty swallowing, Oil†; Oilatum Cream†; Parapsyllium; Transulose; Ger.: Allergika†; Balneum Fire risk. Burns to the scalp, face, and hands have been F; Cellosorb; Coliquifilm; Excipial; Gleitgelen; Oleobal; Parfenac Basisbad†; 1 or to those with impaired neurodevelopment. Vita-POS; Windol Basisbad†; Gr.: Duratears; Hong Kong: Alpha Keri; Bal- reported in 5 patients who accidentally ignited their hair after Some licensed product information warns that chronic ingestion neum; Duratears; Ego Skin Cream; Egozite Baby Cream; Hydromol†; Oila- the application of paraffin-based hair grease. Four patients suf- of liquid paraffin may rarely be associated with impaired absorp- tum Cream; Oilatum Plus; Polytar Emollient; Soov Prickly Heat; India: Aga- fered inhalation injury, 2 of whom required intubation. The death tion of fat-soluble vitamins and possibly other compounds. rol†; Cetraben; Cremaffin; Easylax; Indon.: Laxadine; Oilatum Plus; Yanthi of a patient who, while smoking, ignited bandages covering a Baby Oil; Irl.: Emulsiderm; Hydromol†; Lacri-Lube; Oilatum Emollient; Oil- 2 There is little published evidence to support this. Prolonged use atum Junior; Oilatum Junior Flare-Up; Oilatum Plus; Polytar Emollient†; Is- paraffin-based ointment for psoriasis, prompted the BNF to rec- should, however, be avoided. Liquid paraffin should not be used rael: Balneum F; CleanEars; Duratears; Emulsiderm; Lacrimol; Ital.: Bal- ommend that patients should be told not to smoke and to keep when abdominal pain, nausea, or vomiting is present. The UK neum Hermal Forte; Duolaxan†; Lacrilube; Malaysia: Balneum; Duratears away from flames when using paraffin-based emollients. Naturale; Ego Skin Cream; Egozite Baby Cream; Lacrilube†; Oilatum; Oila- CSM considers that it should not be used in children under 3 tum Plus Antibacterial; QV Flare Up; Soov Prickly Heat†; Mex.: Acuafil†; 1. Bascom R, et al. Inhalation injury related to use of petrolatum- years of age. Milpar; Neth.: Duratears Z; Transulose; Norw.: Simplex; NZ: Alpha Keri; based hair grease. J Burn Care Rehabil 1984; 5: 327–30. BK; DP; DP Lotion - HC; Ego Skin Cream; Egozite Baby; Hydroderm; Kari- 2. National Patient Safety Agency. Skin treatment fire risk. Patient Granuloma. References. care Breast and Body Cream†; Lacrilube; Oilatum Plus; Poly-Visc; Polytar Safety Bulletin 2007 (Jan.); 4. Available at: http:// 1. Di Benedetto G, et al. Paraffin oil injection in the body: an obso- Emollient; Philipp.: Oilatum; Oilatum Plus; Pol.: Amfobase; Balneum Her- www.npsa.nhs.uk/EasySiteWeb/GatewayLink.aspx?alId=6341 lete and destructive procedure. Ann Plast Surg 2002; 49: 391–6. mal F; Diprobase; E45; Mentho-Paraffinol; Oilatum Plus; Unibasis; Port.: (accessed 29/08/08) Banholeum Gele; Betacade†; Melaxose; Oleoban Gel†; S.Afr.: Oilatum Lipoid pneumonia. References. Plus; Singapore: Balneum; DermaVeen Shower & Bath; Duratears; Ego Hypersensitivity. The allergenicity of soft paraffin products 1. Becton DL, et al. Lipoid pneumonia in an adolescent girl second- Skin Cream; Egozite
Load more

Recommended publications
  • Laxatives for the Management of Constipation in People Receiving Palliative Care (Review)
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by UCL Discovery Laxatives for the management of constipation in people receiving palliative care (Review) Candy B, Jones L, Larkin PJ, Vickerstaff V, Tookman A, Stone P This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2015, Issue 5 http://www.thecochranelibrary.com Laxatives for the management of constipation in people receiving palliative care (Review) Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 2 OBJECTIVES ..................................... 4 METHODS ...................................... 4 RESULTS....................................... 7 Figure1. ..................................... 8 Figure2. ..................................... 9 Figure3. ..................................... 10 DISCUSSION ..................................... 13 AUTHORS’CONCLUSIONS . 14 ACKNOWLEDGEMENTS . 14 REFERENCES ..................................... 15 CHARACTERISTICSOFSTUDIES . 17 DATAANDANALYSES. 26 ADDITIONALTABLES. 26 APPENDICES ..................................... 28 WHAT’SNEW..................................... 35 HISTORY....................................... 35 CONTRIBUTIONSOFAUTHORS . 36 DECLARATIONSOFINTEREST . 36 SOURCESOFSUPPORT . 36 DIFFERENCES
    [Show full text]
  • And Dietary Measures Literature Review on the Effect of Laxative Treatment
    Downloaded from adc.bmj.com on 28 August 2008 Currently recommended treatments of childhood constipation are not evidence based. A systematic literature review on the effect of laxative treatment and dietary measures Maaike A. M. Pijpers, Merit Tabbers, Marc A. Benninga and Marjolein Y. Berger Arch. Dis. Child. published online 19 Aug 2008; doi:10.1136/adc.2007.127233 Updated information and services can be found at: http://adc.bmj.com/cgi/content/abstract/adc.2007.127233v1 These include: Rapid responses You can respond to this article at: http://adc.bmj.com/cgi/eletter-submit/adc.2007.127233v1 Email alerting Receive free email alerts when new articles cite this article - sign up in the box at the service top right corner of the article Notes Online First contains unedited articles in manuscript form that have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Online First articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Online First articles must include the digital object identifier (DOIs) and date of initial publication. To order reprints of this article go to: http://journals.bmj.com/cgi/reprintform To subscribe to Archives of Disease in Childhood go to: http://journals.bmj.com/subscriptions/ Downloaded from adc.bmj.com on 28 August 2008 ADC Online First, published on August 19, 2008 as 10.1136/adc.2007.127233 Currently recommended treatments of childhood constipation are not evidence based. A systematic literature review on the effect of laxative treatment and dietary measures.
    [Show full text]
  • Assessment Report on Cassia Senna L
    European Medicines Agency Evaluation of Medicines for Human Use London, 27 April 2007 Doc. Ref. EMEA/HMPC/51868/2006 Corr. COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) ASSESSMENT REPORT ON CASSIA SENNA L. AND CASSIA ANGUSTIFOLIA VAHL, FOLIUM Herbal substance Cassia senna L. (C. acutifolia Delile) [Alexandrian or Khartoum senna] or Cassia angustifolia Vahl [Tinnevelly senna], folium (senna leaf) or a mixture of the two species Herbal preparation dried leaflets, standardised; standardised herbal preparations thereof Pharmaceutical forms Herbal substance for oral preparation Rapporteur Dr C. Werner Assessor Dr B. Merz Superseded 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 51 E-mail: [email protected] http://www.emea.europa.eu ©EMEA 2007 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged TABLE OF CONTENTS I. Introduction 3 II. Clinical Pharmacology 3 II.1 Pharmacokinetics 3 II.1.1 Phytochemical characterisation 3 II.1.2 Absorption, metabolism and excretion 4 II.1.3 Progress of action 5 II.2 Pharmacodynamics 5 II.2.1 Mode of action 5 • Laxative effect 5 II.2.2 Interactions 7 III. Clinical Efficacy 7 III.1 Dosage 7 III.2 Clinical studies 8 III.2.1 Constipation 8 III.2.2 Irritable bowel syndrome 10 III.2.3 Bowel cleansing 11 III.3 Clinical studies in special populations 15 III.3.1 Use in children 15 III.3.2 Use during pregnancy and lactation 16 III.4 Traditional use 17 IV.
    [Show full text]
  • Laxatives Or Methylnaltrexone for the Management of Constipation in Palliative Care Patients (Review)
    Laxatives or methylnaltrexone for the management of constipation in palliative care patients (Review) Candy B, Jones L, Goodman ML, Drake R, Tookman A This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2011, Issue 1 http://www.thecochranelibrary.com Laxatives or methylnaltrexone for the management of constipation in palliative care patients (Review) Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 3 BACKGROUND .................................... 4 OBJECTIVES ..................................... 4 METHODS...................................... 5 RESULTS....................................... 7 Figure1. ..................................... 8 Figure2. ..................................... 9 DISCUSSION ..................................... 13 AUTHORS’CONCLUSIONS . 14 ACKNOWLEDGEMENTS . 15 REFERENCES..................................... 15 CHARACTERISTICSOFSTUDIES . .. 17 DATAANDANALYSES. 28 Analysis 1.1. Comparison 1 Methylnaltrexone versus placebo, Outcome 1 Proportion who had rescue-free laxation within 4hours..................................... 28 Analysis 1.2. Comparison 1 Methylnaltrexone versus placebo, Outcome 2 Laxation within 24 hours. 29 Analysis 1.3. Comparison 1 Methylnaltrexone versus placebo, Outcome 3 Tolerability: proportion
    [Show full text]
  • Docusate Sodium
    HEAD 03150148P00290148L03-M045UWASS FRONT 1ST BAR 1ST BAR >> READ DIRECTION >> READ DIRECTION 100 mg Capsules docusate sodium LAST BAR LAST BAR Package Leaflet: Information for the user Read all of this leaflet carefully before you • Constipation is an occasional problem for start taking this medicine because it some people - for others, it may happen contains important information for you. more often Always take this medicine exactly as described • Constipation happens when the normal in this leaflet or as your doctor or pharmacist muscle actions in the bowel slow down has told you. The cause of constipation is often not known. • Keep this leaflet. You may need to read it It can be linked with: again • Pregnancy • Ask your pharmacist if you need more • Lack of exercise information or advice • Sudden change of diet • If you get any side effects, talk to your • A diet with not enough fibre doctor or pharmacist. This includes any • Having to stay in bed for a long time possible side effects not listed in this leaflet. • Medicines such as morphine or codeine See section 4 • Loss of ‘tone’ of the bowel muscles in older • You must talk to a doctor or pharmacist if people you do not feel better or you feel worse • The full name of your medicine is DulcoEase Whatever the cause, constipation can be 100 mg Capsules. In this leaflet the shorter uncomfortable. It may make you feel bloated name DulcoEase is used and heavy or generally ‘off colour’. Sometimes it causes headaches. What is in this leaflet: Try these healthy tips to help prevent 1.
    [Show full text]
  • Gastroenterologíayhepatología
    Document downloaded from http://www.elsevier.es, day 14/02/2018. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited. Gastroenterol Hepatol. 2017;40(4):303---316 Gastroenterología y Hepatología www.elsevier.es/gastroenterologia REVIEW Clinical practice guidelines for the management of constipation in adults. Part 2: Diagnosis ଝ,ଝଝ and treatment a,∗ b,c d e Jordi Serra , Juanjo Mascort-Roca , Mercè Marzo-Castillejo , Silvia Delgado Aros , f g h Juan Ferrándiz Santos , Enrique Rey Diaz Rubio , Fermín Mearin Manrique a Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain b CAP Florida Sud, Institut Català de la Salut, Hospitalet de Llobregat, Barcelona, Spain c Departament de Ciències Clíniques, Campus Bellvitge, Facultat de Medicina, Universitat de Barcelona, Hospitalet de Llobregat, Barcelona, Spain d Unitat de Suport a la Recerca --- IDIAP Jordi Gol. Direcció d’Atenció Primària Costa de Ponent, Institut Català de la Salut, Comité Científico de semFYC, Barcelona, Spain e Neuro-Enteric Translational Science (NETS) group coordinator. IMIM --- Parc de Salut Mar. PRBB, Barcelona, Spain f Subdirección General de Calidad Asistencial, Consejería de Sanidad, Madrid, Spain g Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain h Instituto de Trastornos Funcionales y Motores Digestivos, Servicio de Aparato Digestivo, Centro Médico Teknon, Barcelona, Spain Received 18 January 2016; accepted 5 February 2016 Available online 31 March 2017 KEYWORDS Abstract Constipation is a very common disorder that adversely affects well-being and quality Constipation; of life. Evidence-based clinical practice guidelines are an essential element for proper patient management and safe, effective treatment.
    [Show full text]
  • Original Article Sep 2010; Vol 20 (No 3), Pp: 291-296
    Iran J Pediatr Original Article Sep 2010; Vol 20 (No 3), Pp: 291-296 Comparing Oral Route Paraffin Oil versus Rectal Route for Disimpaction in Children with Chronic Constipation; a Randomized Control Trial Fatemeh Farahmand1,2, MD; Kambiz Eftekhari2, MD; Vajiheh Modarresi*2, MD; Mehri Najafi-Sani1,2, MD; Ahmad Khodadad1,2, MD, and Farzaneh Motamed1,2, MD 1. Department of Pediatrics, Faculty of medicine, Tehran University of Medical Sciences, Tehran, IR Iran 2. Pediatrics Center of Excellence, Children's Medical Center, Tehran, IR Iran Received: Sep 17, 2009; Final Revision: Nov 18, 2009; Accepted: Feb 10, 2010 Abstract Objective: Functional constipation is a common and challenging problem in pediatrics. Fecal disimpaction prior to maintenance therapy is recommended to ensure successful treatment. The aim of this study was to compare the efficacy and patient’s compliance of the two methods of paraffin oil administration (oral and rectal route) with the purpose of disimpaction in treatment of children with functional constipation. Methods: A total of 80 children (49 males and 31 females) aged 1-12 years, with functional constipation according to Rome III criteria, whose rectal examination confirmed fecal impaction were divided into two groups randomly. Group I received 3 ml/kg/day paraffin oil orally and group II received 3ml/kg/day paraffin oil rectally during 3 consequent days. Successful treatment was defined as no detectable fecal impaction in rectal examination after at most 72 hours. Patient compliance and family satisfaction also was evaluated using a scored questionnaire. Findings: Response to the treatment in both groups was with 92.5% and 82.5% in group I and II, respectively.
    [Show full text]
  • Senna (Cas No
    NTP REPORT ON THE TOXICOLOGY STUDY OF SENNA (CAS NO. 8013-11-4) IN C57BL/6NTAC MICE AND TOXICOLOGY AND CARCINOGENESIS STUDY OF SENNA IN GENETICALLY MODIFIED C3B6.129F1/Tac-Trp53tm1Brd N12 HAPLOINSUFFICIENT MICE (FEED STUDIES) NATIONAL TOXICOLOGY PROGRAM P.O. Box 12233 Research Triangle Park, NC 27709 April 2012 NTP GMM 15 NIH Publication No. 12-5968 National Institutes of Health Public Health Service U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES FOREWORD The National Toxicology Program (NTP) is an interagency program within the Public Health Service (PHS) of the Department of Health and Human Services (HHS) and is headquartered at the National Institute of Environmental Health Sciences of the National Institutes of Health (NIEHS/NIH). Three agencies contribute resources to the program: NIEHS/NIH, the National Institute for Occupational Safety and Health of the Centers for Disease Control and Prevention (NIOSH/CDC), and the National Center for Toxicological Research of the Food and Drug Administration (NCTR/FDA). Established in 1978, the NTP is charged with coordinating toxicological testing activities, strengthening the science base in toxicology, developing and validating improved testing methods, and providing information about potentially toxic substances to health regulatory and research agencies, scientific and medical communities, and the public. The Genetically Modified Model (GMM) Report series began in 2005 with studies conducted by the NTP. The studies described in the GMM Report series are designed and conducted to characterize and evaluate the toxicologic potential, including carcinogenic activity, of selected agents in laboratory animals that have been genetically modified. These genetic modifications may involve inactivation of selected tumor suppressor functions or activation of oncogenes that are commonly observed in human cancers.
    [Show full text]
  • The Treatment of Constipation in Mental Hospitals
    Gut: first published as 10.1136/gut.3.1.85 on 1 March 1962. Downloaded from Gut, 1962, 3, 85 The treatment of constipation in mental hospitals L. R. C. HAWARD AND H. E. HUGHES-ROBERTS From Graylingwell Hospital, Chichester SYNOPSIS This study investigates the incidence of constipation in two representative mental institutions, and the effect, in one of the hospitals, restricting the use of laxatives to only one drug, namely, standardized senna (Senokot). The remarkable potentiality of Senokot for long-term re-educative programmes is reflected in the reduction from 44% of 210 patients receiving various laxatives regularly at the'start of the trial to 8 % after three months' treatment. The special studies showed that chronic psychotics could be freed from enemas and a substantial number (17 out of 24) cured of constipation; 31 patients on insulin therapy required maintenance doses during treatment but all were subsequently cured; of 25 patients with various neurological lesions, 21 were freed of laxative treatment with four only remaining on sub-laxative doses. There exists a two-way psychosomatic relationship large number of psychiatrists each possessing his whereby brain and bowel function influence each own idea of what constitutes the disorder, it was other. Alvarez (1948), for example, has shown that found necessary to employ the basis of the actual nervous tension particularly affects the bowel prescription of an aperient. http://gut.bmj.com/ muscles; conversely, Nobbs (1960) has found that a loaded bowel can cause mental confusion in the elderly and that the correction of constipation INCIDENCE restores the mental equilibrium. In examining the Forms were circulated to the pharmacy departments problems of bowel regularity in a mental hospital we of mental hospitals in England asking for details of are, therefore, studying a pertinent and not un- the use of laxatives.
    [Show full text]
  • Use of Polyethylene Glycol in Functional Constipation and Fecal Impaction Miguel Mínguez1, Antonio López Higueras2 and Javier Júdez3 1Department of Digestive Medicine
    1130-0108/2016/108/12/790-806 REVISTA ESPAÑOLA DE ENFERMEDADES DIGESTIVAS REV ESP ENFERM DIG © Copyright 2016. SEPD y © ARÁN EDICIONES, S.L. 2016, Vol. 108, N.º 12, pp. 790-806 REVIEW Use of polyethylene glycol in functional constipation and fecal impaction Miguel Mínguez1, Antonio López Higueras2 and Javier Júdez3 1Department of Digestive Medicine. Hospital Clínico. Universidad de Valencia. Valencia, Spain. 2Hospital General Universitario Morales Meseguer. Murcia, Spain. 3Knowledge Management. Sociedad Española de Patología Digestiva (SEPD). Madrid, Spain ABSTRACT INTRODUCTION Objective: The objective of this study was to evaluate in an Functional constipation (FC), defined by the Rome Cri- analytical and descriptive manner the evidence published so far on teria (1) as a chronic functional digestive condition, is a the use of polyethylene glycol (PEG), with or without electrolytes, in the management of functional constipation and the treatment serious problem for adults and children due both to its of fecal impaction. prevalence and to the concomitant reduction in quality of Methodology: Search on MEDLINE, EMBASE and Cochrane life. In addition, it implies a high pharmaceutical cost. databases until May 2016 of all publications adjusted to the follow- Likewise, fecal impaction can lead to a situation that ing terms: constipation AND/OR fecal impaction AND (PEG OR seriously compromises patient health, especially at extreme polyethylene glycol OR macrogol OR movicol OR idralax OR miralax OR transipeg OR forlax OR golytely OR isocolan OR ages, causing sometimes a vital risk. mulytely) NOT colonoscopy. Critical reading of selected articles In order to treat these pathologies, a variety of resources (English or Spanish), sorting their description according to group has been employed, including pharmaceutical resources age (adult/pediatric age) and within those, in accordance with study and others that directly impinge upon patient life habits.
    [Show full text]
  • Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
    LEGEMIDDELSTATISTIKK 2019:2 Reseptregisteret 2014–2018 The Norwegian Prescription Database 2014–2018 Reseptregisteret 2014–2018 The Norwegian Prescription Database 2014–2018 Christian Lie Berg Kristine Olsen Solveig Sakshaug Utgitt av Folkehelseinstituttet / Published by Norwegian Institute of Public Health Område for Helsedata og digitalisering Avdeling for Legemiddelstatistikk Juni 2019 Tittel/Title: Legemiddelstatistikk 2019:2 Reseptregisteret 2014–2018 / The Norwegian Prescription Database 2014–2018 Forfattere/Authors: Christian Berg, redaktør/editor Kristine Olsen Solveig Sakshaug Acknowledgement: Julie D. W. Johansen (English text) Bestilling/Order: Rapporten kan lastes ned som pdf på Folkehelseinstituttets nettsider: www.fhi.no / The report can be downloaded from www.fhi.no Grafisk design omslag: Fete Typer Ombrekking: Houston911 Kontaktinformasjon / Contact information: Folkehelseinstituttet / Norwegian Institute of Public Health Postboks 222 Skøyen N-0213 Oslo Tel: +47 21 07 70 00 ISSN: 1890-9647 ISBN: 978-82-8406-014-9 Sitering/Citation: Berg, C (red), Reseptregisteret 2014–2018 [The Norwegian Prescription Database 2014–2018] Legemiddelstatistikk 2019:2, Oslo, Norge: Folkehelseinstituttet, 2019. Tidligere utgaver / Previous editions: 2008: Reseptregisteret 2004–2007 / The Norwegian Prescription Database 2004–2007 2009: Legemiddelstatistikk 2009:2: Reseptregisteret 2004–2008 / The Norwegian Prescription Database 2004–2008 2010: Legemiddelstatistikk 2010:2: Reseptregisteret 2005–2009. Tema: Vanedannende legemidler / The Norwegian
    [Show full text]
  • Prucalopride (Resolor) for Adult Males with Chronic Constipation – Third Line
    Horizon Scanning Centre September 2014 Prucalopride (Resolor) for adult males with chronic constipation – third line SUMMARY NIHR HSC ID: 10238 Prucalopride (Resolor) is intended to be used as third line therapy for the treatment of chronic constipation in adult males. If licensed, it would offer an additional treatment option for this patient group who do not respond to at least two previous laxative treatments. Prucalopride is a highly selective This briefing is serotonin 5-HT4 receptor antagonist that has demonstrated prokinetic properties on gastric, intestinal and colonic smooth muscle. Prucalopride is based on currently licensed for the treatment of chronic constipation in women in information whom laxatives fail to provide adequate relief. available at the time of research and a It is estimated that the prevalence of chronic constipation is 16%. It is more limited literature common in women than men and prevalence increases with age. Patients search. It is not with constipation report a decreased quality of life, more job absenteeism, intended to be a and loss of work productivity. In 2012, there were 60,567 admissions for definitive statement constipation in England, resulting in 151,319 bed days and 72,567 finished on the safety, consultant episodes; in the same year there were 58 deaths registered in efficacy or England and Wales due to constipation. effectiveness of the health technology Management of chronic constipation may involve dietary and lifestyle covered and should changes in addition to medication such as bulk-forming laxatives, stimulant not be used for laxatives, osmotic laxatives or faecal softeners. When oral laxative therapy is commercial ineffective, use of suppositories, enemas, lubiprostone, prucalopride (for purposes or women), rectal irrigation or manual disimpaction may be appropriate.
    [Show full text]